200 related articles for article (PubMed ID: 16166607)
1. A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project.
Bromley E
Schizophr Bull; 2005 Oct; 31(4):954-61. PubMed ID: 16166607
[TBL] [Abstract][Full Text] [Related]
2. Drug initiatives to improve cognitive function.
Marder SR
J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
[TBL] [Abstract][Full Text] [Related]
3. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
[TBL] [Abstract][Full Text] [Related]
4. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
[TBL] [Abstract][Full Text] [Related]
5. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
[TBL] [Abstract][Full Text] [Related]
6. Functional neuroimaging and electrophysiology biomarkers for clinical trials for cognition in schizophrenia.
Cho RY; Ford JM; Krystal JH; Laruelle M; Cuthbert B; Carter CS
Schizophr Bull; 2005 Oct; 31(4):865-9. PubMed ID: 16166611
[TBL] [Abstract][Full Text] [Related]
7. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
Kern RS; Nuechterlein KH; Green MF; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Mintz J; Seidman LJ; Stover E; Marder SR
Am J Psychiatry; 2008 Feb; 165(2):214-20. PubMed ID: 18172018
[TBL] [Abstract][Full Text] [Related]
8. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
9. [Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery].
Sato T; Sora I
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):241-4. PubMed ID: 22256613
[TBL] [Abstract][Full Text] [Related]
10. Wayne Fenton's impact on academic neuroscience.
Geyer MA; Tamminga CA
Schizophr Bull; 2007 Sep; 33(5):1156-9. PubMed ID: 17617663
[TBL] [Abstract][Full Text] [Related]
11. [Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].
Rodríguez-Jiménez R; Bagney A; Moreno-Ortega M; García-Navarro C; Aparicio AI; López-Antón R; de la Oliva J; Jiménez-Arriero MÁ; Santos JL; Lobo A; Palomo T
Rev Neurol; 2012 Nov; 55(9):549-55. PubMed ID: 23111994
[TBL] [Abstract][Full Text] [Related]
12. Developing drugs for cognitive impairment in schizophrenia.
Breier A
Schizophr Bull; 2005 Oct; 31(4):816-22. PubMed ID: 16150959
[TBL] [Abstract][Full Text] [Related]
13. Stimulating the development of drug treatments to improve cognition in schizophrenia.
Green MF
Annu Rev Clin Psychol; 2007; 3():159-80. PubMed ID: 17716052
[TBL] [Abstract][Full Text] [Related]
14. Applying new approaches from cognitive neuroscience to enhance drug development for the treatment of impaired cognition in schizophrenia.
Carter CS
Schizophr Bull; 2005 Oct; 31(4):810-5. PubMed ID: 16107584
[TBL] [Abstract][Full Text] [Related]
15. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.
Harvey PD; Green MF; Keefe RS; Velligan DI
J Clin Psychiatry; 2004 Mar; 65(3):361-72. PubMed ID: 15096076
[TBL] [Abstract][Full Text] [Related]
16. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder.
Green MF
J Clin Psychiatry; 2006 Oct; 67(10):e12. PubMed ID: 17107235
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing separable domains of cognition in human and animal studies: what separations are optimal for targeting interventions? A summary of recommendations from breakout group 2 at the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Nuechterlein KH; Robbins TW; Einat H
Schizophr Bull; 2005 Oct; 31(4):870-4. PubMed ID: 16150960
[TBL] [Abstract][Full Text] [Related]
18. [Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].
Sarolta K; Pál C; István B
Neuropsychopharmacol Hung; 2007 Oct; 9(3):143-50. PubMed ID: 18399033
[TBL] [Abstract][Full Text] [Related]
19. Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.
Marder SR; Fenton W
Schizophr Res; 2004 Dec; 72(1):5-9. PubMed ID: 15531402
[TBL] [Abstract][Full Text] [Related]
20. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
Marder SR
Dialogues Clin Neurosci; 2006; 8(1):109-13. PubMed ID: 16640121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
